Compare LUNG & ECOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LUNG | ECOR |
|---|---|---|
| Founded | 1995 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.9M | 48.6M |
| IPO Year | 2020 | 2018 |
| Metric | LUNG | ECOR |
|---|---|---|
| Price | $1.55 | $8.73 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 1 |
| Target Price | $5.38 | ★ $18.00 |
| AVG Volume (30 Days) | ★ 547.1K | 92.6K |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 7.64 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $90,497,000.00 | $32,032,000.00 |
| Revenue This Year | $2.48 | $33.60 |
| Revenue Next Year | $18.46 | $30.40 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 8.01 | ★ 27.20 |
| 52 Week Low | $1.13 | $4.16 |
| 52 Week High | $3.88 | $9.23 |
| Indicator | LUNG | ECOR |
|---|---|---|
| Relative Strength Index (RSI) | 64.74 | 73.18 |
| Support Level | $1.51 | $4.61 |
| Resistance Level | $1.64 | N/A |
| Average True Range (ATR) | 0.09 | 0.66 |
| MACD | 0.04 | 0.15 |
| Stochastic Oscillator | 79.95 | 86.12 |
Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.
electroCore Inc is a bioelectronic technology company whose mission is to improve health and quality of life through non-invasive bioelectronic technologies. Its two commercial products are gammaCore non-invasive vagus nerve stimulation, or nVNS, and Quell Fibromyalgia, or Quell. It also sells Truvaga and TAC-STIM products, which are handheld, personal-use consumer products developed to promote general wellness and human performance. It operates in one segment: Bioelectronic Innovations. Geographically, it operates in the United States, the United Kingdom, Japan, and Other.